Back to results
US 2026/0265776 A1Published application
Engineered recombinant retroviruses
AssigneeKelonia Therapeutics, Inc.
InventorsKevin M. Friedman, Michael J. McDonald
Life of this patent
Estimating the term…
Abstract
The present disclosure provides recombinant retroviruses engineered to transduce immune effector cells in vivo.
Claims48
A recombinant retrovirus comprising:
- (a) a viral envelope comprising (i) one or more mutated viral envelope glycoproteins that retain fusogenic activity and lack cognate receptor binding activity and (ii) a non-viral membrane-bound tropism polypeptide, and
- (b) a recombinant retroviral vector comprising a polynucleotide encoding a promoter operably linked to a polynucleotide encoding one or more engineered antigen receptors;
- wherein the retroviral vector is engineered or derived from a retrovirus selected from the group consisting of:
- an alpharetrovirus genome, a betaretrovirus genome, a gammaretrovirus genome, a deltaretrovirus genome, an epsilonretrovirus genome, a simiispumavirus genome, a bovispumavirus genome, an equispumavirus genome, a felispumavirus genome, and a prosimiispumavirus genome.
1 more element
Dependencies are inferred from the claim text.